Candidate Drug Targets for Prevention or Modification of Epilepsy
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Epilepsy is a prevalent neurological disorder afflicting nearly 50 million people worldwide. The disorder is characterized clinically by recurrent spontaneous seizures attributed to abnormal synchrony of brain neurons. Despite advances in the treatment of epilepsy, nearly one-third of patients are resistant to current therapies, and the underlying mechanisms whereby a healthy brain becomes epileptic remain unresolved. Therefore, researchers have a major impetus to identify and exploit new drug targets. Here we distinguish between epileptic effectors, or proteins that set the seizure threshold, and epileptogenic mediators, which control the expression or functional state of the effector proteins. Under this framework, we then discuss attempts to regulate the mediators to control epilepsy. Further insights into the complex processes that render the brain susceptible to seizures and the identification of novel mediators of these processes will lead the way to the development of drugs to modify disease outcome and, potentially, to prevent epileptogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“The blood-brain barrier not only limits entry of blood-derived proteins and peripheral cells but also controls the regulated entry of numerous biologically active molecules necessary for maintaining CNS homeostasis, such as potassium, glucose, and amino acids (64).”
Development, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452 · cited 2×
“Dysfunction of the blood-brain barrier can result in ionic imbalances and alterations in neurotransmitter and metabolite distribution, which can culminate in seizures (19).”
The role of inflammation in epilepsy
Vezzani, A., French, J., Bartfai, T., & Baram, T. Z. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.178 · Cited by 1,876 · cited 1×
“IL-1 cytokines are expressed in the healthy brain at very low levels (78), but increased expression of numerous cytokines, including IL-1β, is observed after seizure activity (79).”
The JAK/STAT signaling pathway
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00963 · Cited by 1,858
Zhan, Y., Paolicelli, R. C., Sforazzini, F., Weinhard, L., Bolasco, G., Pagani, F., Vyssotski, A. L., Bifone, A., Gozzi, A., Ragozzino, D., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3641 · Cited by 1,236
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
TrkB signalling pathways in LTP and learning
Minichiello, L. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2738 · Cited by 1,055 · cited 1×
“TrkB is activated by three neurotrophic factors—BDNF, neurotrophin-3, and neurotrophin-4— to influence multiple processes including neuronal differentiation and survival, long-term potentiation, learning, and memory (107).”
Cited by
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
Varvel, N. H., Neher, J. J., Bosch, A., Wang, W., Ransohoff, R. M., Miller, R. J., & Dingledine, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604263113 · Cited by 357
“S epilepticus (SE) is a serious medical emergency that triggers a series of cellular and molecular events that can result in the development of epilepsy, a chronic neurological disorder characterized by a persistently lowered seizure threshold (1).”
BackgroundSelf-citationAnti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside
Dey, A., Kang, X., Qiu, J., Du, Y., & Jiang, J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.001 · Cited by 215
“Nonetheless, these preclinical studies suggest that PGE2 signaling pathways via EP1 and EP2 receptors are crucially involved in neuroinflammation and neurodegeneration after seizures, and point to EP1 and/or EP2 antagonism as a possible adjunctive therapeutics – given their welldocumented neuroprotection – to treat SE…”
BackgroundSelf-citationmTOR and neuroinflammation in epilepsy: implications for disease progression and treatment
Ravizza, T., Scheper, M., Di Sapia, R., Gorter, J., Aronica, E., & Vezzani, A. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-024-00805-1 · Cited by 141
“In several instances, the therapeutic effects of anti-inflammatory drugs on seizures persisted after the treatment was discontinued, suggesting the achievement of disease-modifying effects, rather than merely symptomatic seizure control 96,98,104,105 .”
Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy
Han, H., Mann, A., Ekstein, D., & Eyal, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0096-2 · Cited by 83
Metadata
- Authors
- Varvel, N. H., Jiang, J., & Dingledine, R.
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2015-01-06
- Volume
- 55
- Issue
- 1
- Pages
- 229-247
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2152665391
- Cited by
- 88
- References
- 15
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Candidate Drug Targets for Prevention or Modification of Epilepsy. https://app.cochat.ai/papers/10.1146/annurev-pharmtox-010814-124607
- The paper
- Varvel, N. H., Jiang, J., & Dingledine, R. (2015). Candidate Drug Targets for Prevention or Modification of Epilepsy. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-010814-124607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.